This has been stimulated by the beneficial, lipid-independent effects of IL-1β blockade on cardiovascular outcome in patients with a previous myocardial infarction and high hs-CRP levels in the CANTOS trial (184). The gene discussed is IL1B; the disease is myocardial infarction.